

## Supplemental material

### Supplemental Table 1. Outcomes during follow up.

All cohort (n=1679)

#### Primary outcome (day 30), n (%)

Stroke or death	<b>50 (3)</b>
Stroke	29 (1.7)
Death	16 (0.9)
Vascular death	5 (0.3)

#### Primary outcome (day 0-90), n (%)

Stroke or death	<b>73 (4.3)</b>
Stroke	39 (2.3)
Death from any cause	28 (1.6)
Vascular death	6 (0.4)

#### Safety outcome (90 days), n (%)

Hemorrhagic event	41 (2.4)
Severe bleeding	14 (0.8)
Intracranial hemorrhage	20 (1.2)

#### Secondary outcomes (90 days), n (%)

TIA	17 (1)
Angina and myocardial infarction	4 (0.3)
Other vascular events	6 (0.4)

TIA: Transient Ischemic Attack

**Supplemental Table 2. Hyperacute, acute management and functional Prognosis.**

	<b>All cohort (n=1679)</b>
Neurological assessment (first 24 hours), n (%)	1509 (90)
Stroke code activation, n (%)	725 (43)
Neurovascular study (first 24 hours), n (%)	1226 (73)
Neurovascular study during admission, n (%)	1584 (94)
<b>Hospitalization, n (%)</b>	<b>1456 (87)</b>
Stroke unit	1123 (66)
Neurology Ward	333 (20)
<b>Reperfusion therapy, n (%)</b>	<b>146 (9)</b>
Intravenous Thrombolysis (IVT)	116 (7)
Mechanical Thrombectomy (MT)	23 (1.4)
IVT+MT	7 (0.4)
<b>Urgent antiplatelet therapy (24 h), n (%)</b>	
Monotherapy	1024 (61)
Double antiplatelet therapy	320 (21)
<b>Discharge antiplatelet therapy, n (%)</b>	
Monotherapy	1235 (75)
Double antiplatelet therapy	410 (24)
<b>Functional prognosis (mRS), n (%)</b>	<b>(n=1489)*</b>
<b>Day 30**</b>	
0-1	935 (64)
2	294 (20)
3-6	230 (16)
<b>Day 90***</b>	
0-1	988 (68)
2	262 (18)
3-6	201 (13)

\*Previous independent patients at admission. \*\*Lost to follow-up (n=30).

\*\*\*Lost to follow-up (n=38).